Compare CET & PRGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CET | PRGO |
|---|---|---|
| Founded | 1929 | 1887 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | N/A | 2013 |
| Metric | CET | PRGO |
|---|---|---|
| Price | $55.25 | $15.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.33 |
| AVG Volume (30 Days) | 24.1K | ★ 2.5M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | 5.12% | ★ 10.28% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.02 |
| P/E Ratio | $6.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.82 | $9.23 |
| 52 Week High | $57.39 | $22.65 |
| Indicator | CET | PRGO |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 62.33 |
| Support Level | $55.12 | $9.68 |
| Resistance Level | $55.74 | N/A |
| Average True Range (ATR) | 0.85 | 0.63 |
| MACD | -0.10 | 0.07 |
| Stochastic Oscillator | 10.08 | 75.20 |
Central Securities Corp is a non-diversified closed-end management investment company. The company's investment objective is long-term growth of capital. It invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.